Note on Development and Implementation of the Dashboard

• Enabling equitable access for LMICs while incentivizing R&D development is core to CEPI’s mission. To help achieve this mission, CEPI has developed an Equitable Access Dashboard (EAD) to help guide discussions with funding applicants/awardees and secure access commitments.

• The tool is based on CEPI’s EA policy and draws on CEPI existing practical learnings. It is intended to be used as an adaptive, rather than a “one size fits all” tool, and includes items with different levels of relevance depending on e.g. candidate clinical stage development, type of awardee, type of funding. The EAD will inform the backbone of the awardee’s EA plan and act as a tracking and monitoring tool for progress and key milestones.

• The EAD was discussed at a meeting of CEPI’s Equitable Access Committee (EAC) in December 2021 and the committee members provided high level comments and endorsed the format of the tool and its use. Following the EAC endorsement, the EAD was integrated as a fundamental part of the discussions with the awardees during the negotiations process.
## Dashboard Elements

### Price
- Agreement on pricing principles based on LMICs affordability
- Develop and agree on price corridor for LMICs based on analogue research (pathogen)
- Price negotiated based on LMICs affordability and business sustainability (e.g. COGs +%, no. of years for investment breakeven)
- Agreement on the pricing details for public disclosure

### Clinical Development
- Regulatory submission strategy defined to ensure product licensure/commercialization in endemic countries
- Support for ‘Enabling Sciences’
- Identified commercial partner & manufacturing sites

### Intellectual property
- Agreement on Public Health Licence inclusion
- IP rights discussed and agreed in line with the asset’s specificities
- Agreement to work on additional candidate on the platform/IP

### Shared risk/benefit
- Ensures CEPI retains certain commercial rights for HICs/UMICs
- Financial benefits/refunds/supply after certain milestones
- No fault compensation mechanism in place
- Share of awardee’s commercial revenues from non-outbreaks [OR equivalent in e.g. doses supply DSN]
- Manufacturing at-risk being initiated

### Data sharing and transparency
- Open access to data, results and publications arising from CEPI funding
- Clinical trial data and results publicly disclosed as per CEPI’s clinical trial policy
- Project materials sharing/project data publicly available in form of animal models, biological samples & disease assay

### Availability and supply
- Tech-transfer to LMICs plan in place
- Access to raw materials/adjuvants to ensure manufacturing sustainability
- Provision to cover pandemic period and clarity on location/ownership/management of stock-pile
- Ensure a resilient supply chain for logistics, storage and administration of vaccines
- Commercialization and launch plan for LMICs shared and discussed
- No of doses secured/population at risk
- Appropriate supply chain in place for affected territories - e.g. storage, packaging

### Underlying principles
- Compliance with CEPI’s third party code
- Compliance with CEPI’s EA policy and other policies